Talphera, Inc. TLPH PHARMA
Company Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -24.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -24.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +176.74% |
| 6 Months: | +33.71% |
| 3 Months: | +40.00% |
| 1 Month: | -16.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.65 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -24.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TLPH Talphera, Inc. PHARMA | 1.19 | -5.17 | $61.77M | 0.00% | -52.04% | -143.36% | -24.45% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.92M | 15.43M | 1.73M | 3.02M | 4.53M | 3.37M | 6.43M | 3.11M | 2.66M | 1.49M | 740.00K | 343.00K | 818.00K | 377.00K | 613.00K | 265.00K | 941.00K | 608.00K | 475.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.00K | 0 | 1.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.94M | 3.69M | 3.42M | 3.45M | 3.95M |
| Operating Income | -8.12M | 7.11M | - | -8.52M | -8.32M | -7.97M | - | -12.07M | -9.94M | -8.86M | - | -8.27M | -7.15M | -9.33M | - | -12.32M | -13.36M | -13.53M | - | -15.85M | -6.83M | -9.04M | -9.14M | -10.02M | -8.63M | -4.94M | -13.57M | -6.63M | -5.33M | - | - | - | -4.27M | -3.75M | - | -2.92M | -3.69M | -3.42M | -3.45M | -3.95M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.92M | -3.49M | -4.44M | -3.77M | -3.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.67M | -3.49M | -4.44M | -3.77M | -2.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.90M | 5.07M | -10.55M | -10.98M | -11.09M | -11.40M | -9.68M | -15.55M | -13.06M | -13.01M | -9.88M | -11.59M | -10.54M | -12.46M | -12.56M | -13.67M | -12.41M | -12.73M | -14.42M | -15.93M | -6.61M | -8.93M | -8.96M | -9.85M | -8.38M | -8.67M | 70.66M | -6.75M | -8.15M | -4.37M | -1.36M | -3.95M | -3.83M | -3.35M | - | -2.59M | -3.49M | -4.44M | -3.77M | -2.56M |
| Diluted EPS | -0.20 | 0.11 | -0.24 | -0.25 | -0.24 | -0.25 | -0.21 | -0.34 | -0.29 | -0.28 | -0.20 | - | - | - | - | - | - | - | - | - | - | - | - | -0.08 | -1.40 | - | 8.58 | -0.94 | - | -0.40 | -0.08 | -0.16 | - | - | - | -0.10 | -0.10 | -0.11 | -0.06 | -0.04 |
| R&D Expense | 7.31M | 5.39M | - | 4.17M | 6.28M | 4.62M | - | 6.92M | 4.90M | 3.91M | - | 3.51M | 3.28M | 3.64M | - | 1.38M | 1.16M | 1.06M | - | 1.41M | 813.00K | 956.00K | 969.00K | 724.00K | 1.42M | 836.00K | 1.09M | 799.00K | 1.05M | 1.55M | 1.18M | 1.43M | 1.91M | 2.05M | - | 1.17M | 1.50M | 1.80M | - | 1.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.07M | 2.39M | 29.50M | 5.22M | 19.26M | 17.36M | 8.00M | 2.15M | 2.29M | 5.42M | - | 0 | 651.00K | 0 | 28.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.75M | 2.59M | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -935.00K | -820.00K | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.35M | 17.54M | 15.25M | 13.51M |
| Operating Income | - | - | - | - | - | - | - | -6.67M | -37.65M | -19.95M | -31.96M | -38.68M | -35.73M | -54.20M | -40.96M | - | -20.35M | -16.89M | -15.25M | -13.48M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.90M | -9.84M | -12.61M | -14.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12M | 134.00K | 394.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 59.14M | -10.29M | -13.00M | -14.36M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.00K | 13.00K | 0 | - | - |
| Net Income | -3.77M | -9.63M | -20.66M | -20.12M | -14.34M | -20.10M | -33.36M | -23.43M | -33.35M | -24.40M | -43.16M | -51.51M | -47.15M | -53.24M | -40.38M | - | 47.76M | -18.40M | -13.00M | -14.29M |
| Diluted EPS | - | - | - | - | - | - | -1.51 | -0.59 | -0.91 | -0.60 | -0.95 | -1.10 | - | - | - | - | 5.72 | -1.29 | -0.50 | -0.34 |
| R&D Expense | - | - | - | 15.50M | 8.19M | 13.62M | 24.91M | 26.29M | 24.52M | 22.49M | 21.40M | 19.41M | 13.14M | 4.66M | 4.02M | 4.09M | 3.34M | 5.55M | 6.72M | 6.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | 6.83M | 40.84M | 64.52M | 110.03M | 86.42M | 127.78M | 99.99M | 75.55M | 120.53M | 91.36M | 66.30M | - | 47.49M | 20.39M | 18.24M | 29.72M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.57M | 11.58M | 9.42M | 20.90M |
| Cash & Equivalents | - | - | - | 6.07M | 7.15M | 3.06M | 7.79M | 47.93M | 88.40M | 60.04M | 107.92M | 80.31M | 52.90M | 87.97M | 14.68M | 27.27M | - | 15.28M | 5.72M | 8.86M | 5.89M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.11M | 1.18M | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 160.00K | 309.00K | - | - | - |
| Total Liabilities | - | - | - | - | - | 16.78M | 23.37M | 30.67M | 36.87M | 39.76M | 94.67M | 105.33M | 112.06M | 116.28M | 132.77M | 122.05M | - | 25.67M | 6.29M | 10.23M | 12.68M |
| Current Liabilities | - | - | - | - | - | 13.41M | 7.84M | 14.33M | 6.87M | 13.73M | 12.78M | 10.19M | 13.66M | 15.93M | 13.61M | 17.64M | - | 13.77M | 4.51M | 2.65M | 3.81M |
| Long Term Debt | - | - | - | - | - | - | 15.28M | 8.53M | 14.36M | 18.02M | 16.38M | 18.64M | 11.37M | 3.38M | 20.52M | 13.14M | 5.01M | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.62M | 5.36M | - | - | - |
| Total Equity | -40.00K | -3.71M | -13.19M | -33.34M | -52.99M | -65.89M | 17.47M | 33.85M | 73.16M | 46.66M | 33.11M | -5.34M | -36.51M | 4.25M | -41.42M | -55.75M | - | 21.81M | 14.11M | 8.00M | 17.04M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.24M | 16.95M | 17.03M | 49.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.42M | -12.22M | -15.29M | -24.58M | -487.00K | - | -19.95M | -29.39M | -29.77M | -29.07M | -51.18M | -38.51M | - | -28.33M | -17.49M | -12.68M | -11.36M |
| Investing Cash Flow | 8.62M | 4.76M | -29.58M | 14.96M | -6.92M | - | 8.20M | 1.81M | -9.97M | -10.88M | -36.56M | 34.14M | - | 36.45M | -528.00K | 3.78M | -14.35M |
| Financing Cash Flow | 11.88M | 3.37M | 49.60M | 49.77M | 47.88M | - | 59.63M | -26.00K | 12.33M | 75.03M | 14.45M | 16.96M | - | -507.00K | 3.47M | 12.04M | 22.74M |
| Capital Expenditure | -111.00K | -4.00K | -2.02M | -826.00K | -3.29M | -5.50M | -1.46M | -3.72M | -2.40M | -819.00K | -3.47M | -1.85M | -1.83M | -364.00K | -100.00K | - | - |
| Free Cash Flow | -19.53M | -12.23M | -17.31M | -25.41M | -3.77M | - | -21.41M | -33.12M | -32.17M | -29.89M | -54.65M | -40.36M | - | -28.70M | -17.59M | -12.68M | -11.36M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.61M | -14.55M | 3.14M | -2.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -22.6% | -721.7% | -103.6% | -184.1% | -483.8% | -1,660.9% | -2,368.1% | -756.3% | - | - | -2,594.3% | - | -48,157.1% |
| Net Margin % | - | - | - | - | - | -1,875.1% | -1,393.6% | -79.4% | -639.3% | -126.7% | -248.6% | -644.3% | -2,192.0% | -2,325.9% | -745.6% | - | - | -2,826.0% | - | -51,035.7% |
| ROE % | 101.4% | 73.0% | 62.0% | 38.0% | 21.8% | -115.1% | -98.6% | -32.0% | -71.5% | -73.7% | 808.6% | 141.1% | -1,108.6% | 128.5% | 72.4% | - | 218.9% | -130.4% | -162.5% | -83.9% |
| ROCE % | - | - | - | - | - | - | - | -6.5% | -51.8% | -17.4% | -35.6% | -62.5% | -34.2% | -69.7% | -84.2% | - | -60.4% | -106.3% | -97.8% | -52.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 9.96% | 5.17M | $6.00M |
| 2 | AIGH Capital Management LLC | 8.87% | 4.60M | $5.34M |
| 3 | Rock Springs Capital Management, LP | 6.91% | 3.59M | $4.16M |
| 4 | Nantahala Capital Management, LLC | 6.73% | 3.49M | $4.05M |
| 5 | Bleichroeder LP | 2.52% | 1.31M | $1.52M |
| 6 | Cantor Fitzgerald, L.P. | 1.71% | 887.48K | $1.03M |
| 7 | Dauntless Investment Group, LLC | 1.44% | 746.05K | $865.42K |
| 8 | Vanguard Capital Management LLC | 1.35% | 701.88K | $814.18K |
| 9 | Caption Management, LLC | 0.99% | 514.97K | $597.36K |
| 10 | Almitas Capital LLC | 0.90% | 467.15K | $541.90K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLPH
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxQTVVTc1ZEVTVSMnNCSExCT0pmVDEtVlRiYkJDSjJBRWl3WGVBVDh2b1JWVFBEb2xsV3ZWRWNpZ3pEVktreDVyNlpvaTNTUWd1ODRndjBkTUl4QktIUmxIV3lrU2hGVlZOaUNUbE9jcGVYWFk4QWJNR28wZDQ4cFB6M3BrSzRxcmc1eTFQck…
$TLPH stock is down 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPX0tMMC10X0JnOXdYc0p2cHpxS1VLME9rUGNEMEdjMjJHN2dibFZ0Zi1ueHNpX3luLTF5ZTRZSDRFajJQYlF2c2I5bjVHUUxHSjJzczFGdkppMUg1Q3BJd3FuMXlNZzQ5alF5cmVFTGNVcGxfTGdFNHc1eWdwN25vOC1yVTl1UlVLWm9HUX…
Talphera Inc. (NASDAQ: TLPH) Share Price, TLPH Stock News, TLPH Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFBYOTJNaTdpZ3FGRzVhNUxwdnpfak9vaG9adEw3cUVDQy1iM2o5ZzJRV2szRzFrU08xa0RNU0UwWGYwZElWMkxhUkx5SkZXbFBzN3JUOEJB?oc=5" target="_blank">Talphera Inc. (NASDAQ: TLPH) Share Price, TLPH Stoc…
TLPH - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5USHpLU1FLNVpfdEJEQVdiQzRueVNCc1dxX21QWUZMUXNqTVBPMVpNTEpDSjNhUkJldXpGT1ZqdC1oWVhtS3c?oc=5" target="_blank">TLPH</a> <font color="#6f6f6f">Finviz</font>…
Price to book forward of Talphera, Inc. – NASDAQ:TLPH - tradingview.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPUkNHdWowLTRWSGk1N2cyU0RhQlE4RHRVd0dYTFY1REM1YlZfRmtYUEdvQm9ZSVgxbl9kblpYM1lVNVUxaVE5UUJKd2J0NjM3UTFjNWtEVUpPbG9nNzNPcncwcHgzZmlYUXNjaWlxdjFXZXI0ckFmeDhYczhyTlVUWDFCM3VrSWUwNnhDOG…
Talphera will webcast its second-quarter financial update Aug. 12 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOZ0tCY0pDNTlUeThVbHZ2ZnB3RDNieHdfM3dCRE0tdGY4Ql8wZjBOdDRWMHZxa3JxYnRlRUUzQmNjM2luX1dCYVl5d2EtdUVGYXRzYmRZX0ZGNVIwRzR0c1VLQndrMnFZYTVaZDVKNzBURHFXSk12TXJIWU5BT0ViYnZMeHVBcXdNZ2d0Rz…
TLPH — Frequently Asked Questions
What is the current share price of Talphera, Inc. (TLPH)?
As of 2026-09-19 21:16 PDT, Talphera, Inc. (TLPH) trades at $1.19 on NasdaqCM. Its 52-week range is $0.43 to $1.47.
What is the market capitalisation of TLPH?
Talphera, Inc. (TLPH) has a market capitalisation of $61.77M on NasdaqCM.
What is the P/E ratio of TLPH?
TLPH trades at a trailing price-to-earnings (P/E) ratio of -5.17. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.14.
What is the return on equity (ROE) of TLPH?
TLPH has a return on equity (ROE) of -143.36%. Its return on capital employed (ROCE) is -52.04%.
Is TLPH a good stock to buy?
This page provides a data-driven analysis of Talphera, Inc. (TLPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.